btw, with much less selection pressure from Relenza and the better fit to the neuraminidase enzyme, my opinon is that clinically relevant resistance is extremely unlikely to emerge with Relenza. More likely that an asteroid hits us! With royalties of at least 25 million coming in over the next year, I can't see BTA's sp going to 20 cents.